Skip to main content
. 2022 Aug 3;81(11):1491–1503. doi: 10.1136/ard-2022-222405

Figure 1.

Figure 1

IRs (patients with first events/100 PY; 95% CIs) for (A) all infections, overall and stratified by age, and (B) all infections excluding HZ; and HRs (95% CIs) for (C) all infections, overall and stratified by age, and (D) all infections excluding HZ, in ORAL Surveillance. HRs are shown on a logarithmic scale. For patients randomised to the tofacitinib 10 mg two times per day group who had their dose of tofacitinib reduced to 5 mg two times per day, the data collected after patients were switched to tofacitinib 5 mg two times per day were counted in the tofacitinib 10 mg two times per day group. *Excludes HZ adjudicated as opportunistic infections and non-adjudicated HZ events from the clinical database. †HRs (95% CIs) based on a simple Cox proportional hazard model for pairwise treatment comparisons, with treatment as covariate. ‡HRs (95% CIs) based on a multivariable Cox proportional hazard model for pairwise treatment comparisons with treatment, sex, region and smoking as covariates. BID, two times per day; HR, hazard ratio; HZ, herpes zoster; IR, incidence rate; N, number of evaluable patients; n, number of patients with events; PY, patient-years; TNFi, tumour necrosis factor inhibitors.